Journal
THROMBOSIS RESEARCH
Volume 130, Issue -, Pages S63-S65Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2012.08.279
Keywords
-
Categories
Funding
- Celgene
- Janssen
- Onyx
- Novartis
- Amgen
- LeoPharma
Ask authors/readers for more resources
Survival of myeloma patients has improved since the introduction of novel agents in the armamentorium, especially with the Immunomodulator drugs (IMiDs). However, this substantial benefit has been counterbalanced by the dramatic increase of the incidence rate of thromboembolic events, either venous and/ or arterial. This observation has made compulsory a prophylactic treatment in myeloma treated with IMiDs. Although guidelines were proposed since, it is clear that several unanswered questions remain, starting with the choice of the thromboprophylaxis and the definition of risk factors. Further studies are warranted to help decide the optimal thromboprophylaxis. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available